UnitedHealth Group Incorporated

UnitedHealth Group closed at roughly $285, near the bottom of its 52-week range of $255.97 to $461.62. The stock carries a P/E of 25.63, above the broader market but reflecting a sharp 32.7% decline in trailing EPS, which stands at $15.55. Revenue grew 6.5% year-over-year, but the net margin compressed to 3.1%. The Alpha Score of 43.2 places the company in the 'neutral' zone, with momentum (51.5) and sentiment (50) near the midline, while value (35.2) and quality (35.9) are depressed. The earnings drop appears to be the primary drag on the valuation and investor sentiment. Forward watch: The next quarterly report will be the key catalyst. Investors will look for signs of margin recovery and whether the EPS decline is bottoming. Any update on medical cost trends or regulatory changes in the healthcare sector could also drive the stock.

UnitedHealth shares sit near the lower end of their 52-week range after a year that saw EPS fall 32.7% even as revenue grew 6.5%. The earnings decline, tied to higher medical costs and the Change Healthcare cyberattack fallout, pushed the stock to roughly $256 at its low before a partial recovery. Net margin sits thin at 3.1%, a figure that underscores how much of the top line fails to reach the bottom. The valuation picture reflects the same tension. At a P/E of 25.63, the market is paying for earnings power that has yet to show up in reported results. The Alpha Score of 42.6 captures the disconnect: momentum sits near 49.4, while value and quality both lag in the mid-30s, suggesting the stock's own fundamentals are not driving the multiple. For now, the calendar is the story. First-quarter earnings, due in mid-April, will be the first test of whether the medical-cost pressure that compressed 2024 results has eased. Until then, the stock trades on guidance and sentiment rather than the underlying numbers.

UnitedHealth slid 5% from its Monday intraday high, settling near $435. Revenue grew 6.5% year-over-year, but net margin of 3.1% shows cost pressures in the medical-loss ratio. EPS contracted 32.7% to $15.55 — the steepest annual decline in the company's public history — driven by higher medical costs from Medicare Advantage utilization. The P/E of 25.6 sits above the sector median of 22, reflecting a premium that quality sub-score of 35.9 undercuts. Momentum at 41.2 and value at 44.8 are middling. Sentiment at 50 is flat. Key watch: the company reports Q2 earnings October 17. Management signaled the medical-loss trend in Q1 would moderate by midyear — if it doesn't, the current valuation faces compression.

UnitedHealth Group reported a 32.7% drop in EPS year over year, to $15.55, even as revenue grew 6.5%. Net margin narrowed to 3.1%, the lowest in recent quarters. The stock trades at 25.6 times earnings, near the high end of its five-year range. Its Alpha Score of 42.7 reflects weak momentum (41.9) and quality (35.9), with value (44.8) and sentiment (50) middling. Costco's partnership with SCAN Group to launch a Medicare Advantage plan adds a new competitor in two states. That could pressure UnitedHealth's dominant position in the segment. Watch for enrollment data from the new plan and any impact on UnitedHealth's Medicare Advantage margins in the coming quarters.

UnitedHealth shares traded lower Friday, extending a pullback from the $461 high set in October. Revenue rose 6.5% year over year, but earnings per share dropped 32.7% — the steepest decline in the company's recent history. Net margins compressed to 3.1%, down from roughly 6% a year ago, reflecting higher medical costs tied to Medicare Advantage utilization. The stock sits near the middle of its 52-week range at $359, roughly 20% below the peak. The Alpha Score of 45 reflects middling momentum and value scores, with quality dragging at 35.9. Sentiment at 50 is neutral. Investors will watch the next quarterly filing for signs that medical cost trends are stabilizing. The company's annual outlook, due in January, will be the next major catalyst.